Application 761352

Type
BLA
Sponsor
MERUS N.V.

Purple Book Biologic Products#

BLA, Proprietary name, Proper name table
BLAProprietary nameProper nameLicense typeStatusLatest source
761352Bizengrizenocutuzumab-zbco351(a)Rx2026-06-01

Application Products#

Product, Drug, Ingredient table
ProductDrugIngredientFormStrengthReference drugReference standard
001BIZENGRIZENOCUTUZUMAB-ZBCOINJECTION;SOLUTION375MG/18.75MLNoNo

openFDA label cross-check#

Cross-check layer: openFDA label JSON enriches search and identifies hydration gaps. The DailyMed Structured Product Label remains the canonical label presentation on FDA.report. Every label matching the complete exact-identifier union is deduplicated and paginated below.

Matched openFDA labels page 1 of 1 ยท 2 matching rows.

Brand, Generic, Manufacturer table
BrandGenericManufacturerSPL set IDEffective dateAvailable safety fieldsJoin
BIZENGRIZENOCUTUZUMABPartner Therapeutics, Inc.203daea4-fc87-40a4-a92f-ba2351b16de12026-05-19Boxed warning, Warnings, Adverse reactionsExact identifier
application number: BLA761352
BIZENGRIZENOCUTUZUMABMerus US, Inc.2a33e782-fc75-4dba-b77c-a44536ac13a52025-01-17Boxed warning, Warnings, Adverse reactionsExact identifier
application number: BLA761352

Documents#

Document, Submission type, Date table
DocumentSubmission typeDate
85948SUPPL 2026-05-18
85877SUPPL 2026-05-11
80811ORIG 2025-01-03
80513ORIG 2024-12-05
80507ORIG 2024-12-04